



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



# Salivary Gland NGS Fusion Panel

## Alternative Name

Salivary Gland Fusion Panel

## Methodology

Molecular

## Test Description

The Salivary Gland NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ARID1A, ATF1, CRTC1, CRTC3, DDX3X, ETV6, EWSR1, HMGA2, MAML1, MAML2, MYB, MYBL1, MYH9, NCOA4, NFIB, NTRK1, NTRK2, NTRK3, PLAG1, PRKD1, PRKD2, PRKD3, RET, and USP6.

## Clinical Significance

The Salivary Gland NGS Fusion Panel detects gene fusions that may aid in the classification of the disease and selection of patients for available therapies.

Salivary gland tumors have been reported to harbor gene fusions, such as ETV6-NTRK3, MYB-NFIB, EWSR1-ATF1, CRTC1-MAML2, and CRTC3-MAML2. Studies suggest these fusions could be therapeutic targets.

## Specimen Requirements

- **FFPE tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

## Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

## CPT Code(s)\*

81449

## Medicare MoIDX CPT Code(s)\*

81449

## New York Approved

Yes

## Level of Service

Global

## Turnaround Time

21 Days

## References

1. Inaki R, Abe M, Zong L, et al. Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor. *Chin J Cancer Res.* 2017;29(5):379-384. doi:10.21147/j.issn.1000-9604.2017.05.01

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 102224